William Makis MD

02/21/2026

🚨BREAKING STUDY: Israeli FOIA Data Reveals MASSIVE Heart Damage Spike in Children Immediately After mRNA Shot Rollout

Previously undisclosed government data from Israel show HUNDREDS of 12–16-year-olds suffered severe cardiac injury, including cases coded as HEART ATTACKS, within 6 weeks of mRNA authorization. ⬇️

According to Israel’s State Comptroller, approximately 279,300 adverse event reports submitted during the vaccination campaign by Clalit Health Services — Israel’s largest health provider — were NEVER processed by the Ministry of Health.

Only years later, following repeated Freedom of Information Act (FOIA) requests, the raw dataset was released.

We analyzed that dataset using a deliberately conservative methodology. Our findings have now been peer-reviewed and published in the International Journal of Cardiovascular Research & Innovation, in a study titled, Cardiovascular safety signals in Israeli adolescents following COVID-19 Vaccination: Evidence from an unprocessed FOIA dataset.

FOIA data revealed 277 unique cardiovascular injury cases in teenagers, identified using conservative de-duplication methods.

98% of cases occurred in adolescents aged 12–16 within a narrow six-week window immediately after mRNA eligibility expanded in June 2021.

Hundreds of entries were coded in the national system as “Acute Cardiovascular Injury,” which in the original Hebrew terminology corresponds to acute myocardial infarction (heart attack).

Additional coded events included myocarditis, pericarditis, stroke, and thromboembolism.

When we contacted Clalit Health Services to clarify these adolescent "heart attack" entries, we were told: “The data do not exist.”

These reports existed within Israel’s national surveillance system — but were not processed or publicly analyzed during the critical 2021 policy window.

This data is now peer-reviewed and published for the world to see.

02/21/2026

02/18/2026

02/15/2026

‼️‼️‼️These anecdotal reports suggest potential anti-cancer effects of ivermectin and benzimidazoles, warranting further investigation through rigorous clinical trials.
➡️Abstract
✅Background:
The global burden of advanced-stage cancers remains a significant challenge, particularly in low- and middle-income countries where access to effective therapies is limited. Stage 4 cancers that have undergone extensive prior treatments and lack actionable mutations generally have limited treatment options. With standard chemotherapy, targeted therapies, and immunotherapies, the median overall survival (mOS) typically ranges from 9 to 12 months. Repurposing existing drugs, such as the antiparasitics ivermectin, fenbendazole, and mebendazole, has garnered attention due to anecdotal reports and robust pre-clinical studies suggesting potential anti-cancer effects.
✅Objective:
This article compiles and systematically presents anecdotal case reports and preliminary clinical data on the use of ivermectin and benzimidazoles (fenbendazole and mebendazole) in patients with stage 4 cancers, aiming to provide a foundation for further scientific investigation.
✅Methods:
Case reports were collected from various online sources, including social media platforms (e.g., X/Twitter) and websites, detailing patient experiences with ivermectin and benzimidazoles, often in combination with conventional therapies. Cases are organized by cancer type, with a focus on stage 4 diagnoses, and include reported outcomes such as tumor shrinkage, biomarker reduction, and imaging results.
✅Results:
A total of 260+ case reports across multiple cancer types (breast, brain, bile duct, bladder, cervical, colorectal, esophageal, endometrial, head and neck, kidney, liver, lung, ovarian, pancreatic, prostate, sarcoma, and skin) were compiled. Notable outcomes include significant tumor volume reductions (e.g., up to 99.7% in pancreatic cancer), biomarker decreases (e.g., CA19-9 dropping from 44,960 to 21 in pancreatic cancer), and reports of “cancer-free” status in some cases. A phase I/II clinical trial on ivermectin and balstilimab in metastatic triple-negative breast cancer reported a 37.5% clinical benefit rate.

02/13/2026

🚨RANDOMIZED TRIAL: High-Dose Vitamin C Cuts Death Risk from Stage IV Pancreatic Cancer by 54% and DOUBLES Survival Time

Adding 75g IV vitamin C to chemotherapy DOUBLED median survival compared with chemo alone — in one of the deadliest cancers known ⬇️

Patients were randomized 1:1 to receive either gemcitabine plus nab-paclitaxel alone (n=16) or the same chemotherapy regimen combined with pharmacologic IV vitamin C (75 g, three times weekly) (n=18).

The results were striking in patients with Stage IV pancreatic cancer who received high-dose IV vitamin C:

✅Median overall survival doubled
8.3 months (chemo alone) → 16 months (chemo + IV vitamin C)

✅54% reduction in risk of death
Hazard ratio: 0.46

✅Progression-free survival improved
3.9 months → 6.2 months

✅Higher objective response rate
23% → 38%

✅Lower rates of serious adverse events overall

✅Lower rates of severe hematologic toxicity (e.g., neutropenia)

✅Pharmacologic plasma vitamin C levels achieved (~500-fold increase)

Both groups received identical chemotherapy backbones, meaning the survival difference is attributable to the addition of vitamin C.

In a disease where median survival has historically hovered around 8–11 months, doubling survival warrants serious attention and larger confirmatory trials.

02/12/2026

NEWS: "NCI Launches Preclinical Ivermectin Cancer Study Amid Florida Support"

"Excitement builds from patient stories shared by physicians like Dr.William Makis"

It must be devastating for Grok to go against its Big Pharma programming 😂